Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
793 Combined administration of the dual A2aR/A2bR antagonist etrumadenant with a reduced chemotherapy regimen leads to enhanced tumor efficacy and survival
Compose a Response to This Article
Other responses
No responses have been published for this article.
